Skip to main content
SpringerLink
Log in

PON1 Polymorphisms

  • Chapter
Paraoxonase (PON1) in Health and Disease

Abstract

HDL-associated paraoxonase (PON1) is involved in the metabolism of oxidized lipid species. It also hydrolyzes a number of nerve agents, aromatic esters and toxic metabolites of organophosphorus insecticides. For many years, it has been assumed that high serum levels of PON 1 would protect against exposure to paraoxon, parathion and other OP compounds. Recent studies, however, have shown that PON1 does protect against exposure to the oxon forms of diazinon and chlorpyrifos but not paraoxon. Less protection is seen against the respective parent compounds diazinon and chlorpyrifos. Two polymorphisms have been described in the PON1 coding region, L55M and Q192R. The Q192R polymorphism affects the catalytic efficiency of PON 1 for the hydrolysis of specific OP substrates. Other polymorphisms have been described in the 5’ and 3’ non-coding regions. Several of the 5’ polymorphisms may influence serum PON1 levels that in turn affect rates of substrate hydrolysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • (1996) Update on nomenclature for human gene mutations. Ad Hoc Committee on Mutation Nomenclature. Hum Mutat 8: 197–202

    Google Scholar 

  • Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52: 598–608

    CAS  Google Scholar 

  • Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E (1999) Gln → Arg 191 polymorphism of paraoxonase and Parkinson’s disease. Hum Hered 49: 178–180

    Article  CAS  Google Scholar 

  • Aldridge WN (1953) An enzyme hydrolysing diethyl-p-nitrophenyl phosphate (E-600) and its identity with the A-esterase of mammalian sera. Biochem J. 53: 117–124

    CAS  Google Scholar 

  • Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, et al (1996) The Gln-Argl91 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98: 883–885

    Article  CAS  Google Scholar 

  • Augustinsson KB, Barr M (1963) Age variation in plasma arylesterase activity in children. Clin. Chem. Acta 8: 568–573

    Article  CAS  Google Scholar 

  • Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18: 1617–1624

    Article  CAS  Google Scholar 

  • Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, et al (2000a) Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 71: 1062–1076

    CAS  Google Scholar 

  • Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffiman A, Billicke S, et al (2000b) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510–2517

    Article  CAS  Google Scholar 

  • Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Nacak M, Tapanyigit EE, Roots I (1999) Paraoxonase 1 mutations in a Turkish population. Toxicol Appl Pharmacol 157: 174–177

    Article  CAS  Google Scholar 

  • Aynacioglu AS, Kepekci Y (2000) The human paraoxonase Gln-Argl92 (Q/R) polymorphism in turkish patients with coronary artery disease. Int J Cardiol 74: 33–37

    Article  CAS  Google Scholar 

  • Bauters C, Amant C, Boulier A, Cabrol P, McFadden E, Duriez P, Bertrand ME, et al (2000) Paraoxonase polymorphism (Gln 192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 101: 740–743

    Article  CAS  Google Scholar 

  • Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28: 1335–1342

    CAS  Google Scholar 

  • Blatter Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, James RW (1994) Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 304: 549–554

    Google Scholar 

  • Blatter Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62–66

    Article  Google Scholar 

  • Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE (2001a) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11: 77–84

    Article  CAS  Google Scholar 

  • Brophy VH, Jampsa RL, Clendenning JB, Jarvik GP, Furlong CE (2001b) Promoter polymorphisms affect paraoxonase (PON1) expression. Am J Hum Gene. 68: 1428–1436

    Article  CAS  Google Scholar 

  • Cao H, Girard-Globa A, Berthezene F, Moulin P (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 40: 133–139

    CAS  Google Scholar 

  • Cao H, Girard-Globa A, Serusclat A, Bernard S, Bondon P, Picard S, Berthezene F, et al (1998) Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis 138: 361–366

    Article  CAS  Google Scholar 

  • Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G, Roots I, et al (1999) Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 9: 755–761

    Article  CAS  Google Scholar 

  • Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE (1996) Structural organization of the human PON1 gene. Genomics 35: 586–589

    Article  CAS  Google Scholar 

  • Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14: 334–336

    Article  CAS  Google Scholar 

  • Dessi M, Gnasso A, Motti C, Pujia A, Irace C, Casciani S, Staffa F, et al (1999) Influence of the human paraoxonase polymorphism (PON1 192) on the carotid-wall thickening in a healthy population. Coron Artery Dis 10: 595–599

    Article  CAS  Google Scholar 

  • Diepgen TL, Geldmacher-von Mallinckrodt M (1986) Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. Arch Toxicol Suppl 9: 154–158

    Article  CAS  Google Scholar 

  • Eckerson HW, Romson J, Wyte C, La Du BN (1983a) The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35: 214–227

    CAS  Google Scholar 

  • Eckerson HW, Wyte CM, La Du BN (1983b) The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126–1138

    CAS  Google Scholar 

  • Ecobichon DJ, Stephens DS (1973) Perinatal development of human blood esterases. Clin Pharmacol Ther 14: 41–47

    CAS  Google Scholar 

  • Eiberg H, Mohr J, Schmiegelow K, Nielsen LS, Williamson R (1985) Linkage relationships of paraoxonase (PON) with other markers: indication of PON-cystic fibrosis synteny. Clin Genet 28: 265–271

    Article  CAS  Google Scholar 

  • Fanella S, Harris SB, Young TK, Hanley AJ, Zinman B, Connelly PW, Hegele RA (2000) Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin Chem Lab Med 38: 413–420

    Article  CAS  Google Scholar 

  • Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W (2000) The paraoxonase Leu-Met54 and Gln-Argl91 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152: 421–431

    Article  CAS  Google Scholar 

  • Geldmacher-von M, Rabast U, Lindorf HH (1969) [Differences in the reaction of human serum cholinesterases with E 600 (0,0-diethyl-0-(p-nitrophenyl)-phosphate)]. Arch Toxikol 25: 223–228

    Article  Google Scholar 

  • Geldmacher-von Mallinckrodt M, Diepgen TL (1988) The human serum paraoxonase polymorphism and specificity. Toxicol adn Environ Chem 18: 79–196

    Article  Google Scholar 

  • Geldmacher-von Mallinckrodt M, Diepgen TL, Duhme C, Hommel G (1983) A study of the polymorphism and ethnic distribution differences of human serum paraoxonase. Am J Phys Anthropol 62: 235–241

    Article  Google Scholar 

  • Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, Nicholls DP, et al (1999) Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 56: 289–298

    Article  CAS  Google Scholar 

  • Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE (1991) Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30: 10141–10149

    Article  CAS  Google Scholar 

  • Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, et al (1997) Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 17: 2744–2752

    Article  CAS  Google Scholar 

  • Hegele RA, Brunt JH, Connelly PW (1995) A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 15: 89–95

    Article  CAS  Google Scholar 

  • Heijmans BT, Westendorp RG, Lagaay AM, Knook DL, Kluft C, Slagboom PE (2000) Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149: 91–97

    Article  CAS  Google Scholar 

  • Helbecque N, Cottel D, Meirhaeghe A, Dallongeville J, Amouyel P (1999) Paraoxonase (Glnl92-Arg) polymorphism in French type 2 diabetics [letter]. Atherosclerosis 147: 415–416

    Article  CAS  Google Scholar 

  • Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, et al (1996) The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126: 299–303

    Article  CAS  Google Scholar 

  • Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3: 73–76

    Article  CAS  Google Scholar 

  • Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, et al (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with noninsulin-dependent diabetes mellitus. Metabolism 47: 598–602

    Article  CAS  Google Scholar 

  • Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, et al (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149: 435–442

    Article  CAS  Google Scholar 

  • Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957–3962

    Article  CAS  Google Scholar 

  • James RW, Leviev I, Righetti A (2000a) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101: 2252–2257

    Article  CAS  Google Scholar 

  • James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC (2000b) Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49: 1390–1393

    Article  CAS  Google Scholar 

  • Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000) Paraoxonase phenotype is a better predictor of vascular disease than PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 20: 2441–2447

    Article  CAS  Google Scholar 

  • Kao YL, Donaghue K, Chan A, Knight J, Silink M (1998) A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 83: 2589–2592

    Article  CAS  Google Scholar 

  • Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, et al (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141: 259–264

    Article  CAS  Google Scholar 

  • Kondo I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson’s disease. Brain Res 806: 271–273

    Article  CAS  Google Scholar 

  • Krisch K (1968) [Enzymatic hydrolysis of diethyl-p-nitrophenylphosphate (E 600) by human serum]. Z Klin Chem Klin Biochem 6: 41–45

    CAS  Google Scholar 

  • Kujiraoka T, Oka T, Ishihara M, Egashira T, Fujioka T, Saito E, Saito S, et al (2000) A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41: 1358–1363

    CAS  Google Scholar 

  • La Du BN (1992) Human serum paraoxonase/arylesterase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press, New York, pp 51–91

    Google Scholar 

  • La Du BN, Furlong CE, Reiner E (1999) Recommended nomenclature system for the paraoxonases. Chem Biol Interact 119-120: 599–601

    Article  Google Scholar 

  • Leus FR, Wittekoek ME, Prins J, Kastelein JJ, Voorbij HA (2000) Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 149: 371–377

    Article  CAS  Google Scholar 

  • Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20: 516–521

    Article  CAS  Google Scholar 

  • Leviev I, Negro F, James RW (1997) Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 17: 2935–2939

    Article  CAS  Google Scholar 

  • Li WF, Costa LG, Furlong CE (1993) Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 40: 337–346

    Article  CAS  Google Scholar 

  • Li W-F, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, et al (2000) Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 10: 767–779

    Article  CAS  Google Scholar 

  • Mackness MI, Thompson HM, Hardy AR, Walker CH (1987) Distinction between’ A’-esterases and arylesterases. Implications for esterase classification. Biochem J 245: 293–296

    CAS  Google Scholar 

  • Mackness B, Mackness MI, Airol S, Turkie W, Durrington PN (1997a) Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122: 265–268

    Article  CAS  Google Scholar 

  • Mackness MI, Arrol S, Mackness B, Durrington PN (1997b) Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation [letter]. Lancet 349: 851–852

    Article  CAS  Google Scholar 

  • Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998a) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423: 57–60

    Article  CAS  Google Scholar 

  • Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, et al (1998b) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139: 341–349

    Article  CAS  Google Scholar 

  • Mackness B, Durrington PN, Mackness MI (1998c) Human Serum Paraoxonase (Review). Gen Pharmac 31: 329–336

    Article  CAS  Google Scholar 

  • Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI (2000a) Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Colch) 98: 355–363

    Article  CAS  Google Scholar 

  • Mackness B, Durrington PN, Mackness MI (2000b) Low paraoxonase in persian gulf war veterans self-reporting gulf war syndrome. Biochem Biophys Res Commun 276: 729–733

    Article  CAS  Google Scholar 

  • Mackness B, Mackness MI, Durrington PN, Arrol S, Evans AE, McMaster D, Ferneres J, et al (2000c) Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 30: 4–10

    Article  CAS  Google Scholar 

  • Malin R, Huang XH, Wirta O, Rantalaiho V, Pasternack A, Jokela H, Koivula T, et al. (1998) The Met54Leu polymorphism of paraoxonase (PON) enzyme gene is not a genetic risk factor for non-insulin-dependent diabetes mellitus in Finns [letter]. Clin Genet 54: 254–255

    Article  CAS  Google Scholar 

  • Malin R, Rantalaiho V, Huang XH, Wirta O, Pasternack A, Leinonen JS, Alho H, et al (1999) Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects. Hum Genet 105: 179–180

    CAS  Google Scholar 

  • Murata M, Nakagawa M, Takahashi S (1998) Molecular variant of the human paraoxonase/arylesterase gene is associated with central retinal vein occlusion in the Japanese population. Ophthalmologica 212: 257–259

    Article  CAS  Google Scholar 

  • Nishio E, Watanabe Y (1997) Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols. Biochem Biophys Res Commun 236: 289–293

    Article  CAS  Google Scholar 

  • Odawara M, Tachi Y, Yamashita K (1997) Paraoxonase polymorphism (Glnl92-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82: 2257–2260

    Article  CAS  Google Scholar 

  • Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, et al (1998) The gln-Argl92 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol 18: 1611–1616

    Article  CAS  Google Scholar 

  • Ortigoza-Ferado J, Richter RJ, Hornung SK, Motulsky AG, Furlong CE (1984) Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet 36: 295–305

    CAS  Google Scholar 

  • Padungtod C, Niu T, Wang Z, Savitz DA, Christiani DC, Ryan LM, Xu X (1999) Paraoxonase polymorphism and its effect on male reproductive outcomes among Chinese pesticide factory workers. Am J Ind Med 36: 379–387

    Article  CAS  Google Scholar 

  • Pati N, Pati U (1998) Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 66: 165–168

    Article  CAS  Google Scholar 

  • Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU (1999) Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48: 623–627

    Article  CAS  Google Scholar 

  • Playfer JR, Eze LC, Bullen MF, Evans DA (1976) Genetic polymorphism and interethnic variability of plasma paroxonase activity. J Med Genet 13: 337–342

    Article  CAS  Google Scholar 

  • Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ (1997) The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis 8: 677–682

    Article  CAS  Google Scholar 

  • Richter RJ, Furlong CE (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9: 745–753

    Article  CAS  Google Scholar 

  • Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, et al (1995) Gln-Argl92 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes [see comments]. Lancet 346: 869–872

    Article  CAS  Google Scholar 

  • Sakai T, Matsuura B, Onji M (1998) Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 37: 581–584

    Article  CAS  Google Scholar 

  • Salonen JT, Malin R, Tuomainen TP, Nyyssonen K, Lakka TA, Lehtimaki T (1999) Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study [see comments]. BMJ 319: 487–489; discussion 490

    Article  CAS  Google Scholar 

  • Sanghera DK, Aston CE, Saha N, Kamboh MI (1998a) DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease [see comments]. Am J Hum Genet 62: 36–44

    Article  CAS  Google Scholar 

  • Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17: 1067–1073

    Article  CAS  Google Scholar 

  • Sanghera DK, Saha N, Kamboh MI (1998b) The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 136: 217–223

    Article  CAS  Google Scholar 

  • Schmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, Watzinger N, Hartung HP, et al (1998) Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 29: 2043–2048

    Article  CAS  Google Scholar 

  • Sen-Banerjee S, Siles X, Campos H (2000) Tobacco Smoking Modifies Association Between Gln-Argl92 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction. Arterioscler Thromb Vasc Biol 20: 2120–2126

    Article  CAS  Google Scholar 

  • Senti M, Aubo C, Elosua R, Sala J, Tomas M, Marrugat J (2000a) Effect of physical activity on lipid levels in a population-based sample of men with and without the Argl92 variant of the human paraoxonase gene. Genet Epidemiol 18: 276–286

    Article  CAS  Google Scholar 

  • Senti M, Aubo C, Tomas M (2000b) Differential effects of smoking on myocardial infarction risk according to the Gln/Arg 192 variants of the human paraoxonase gene. Metabolism 49: 557–559

    Article  CAS  Google Scholar 

  • Serrato M, Marian AJ (1995) A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96: 3005–3008

    Article  CAS  Google Scholar 

  • Sheets MD, Ogg SC, Wickens MP (1990) Point mutations in AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. Nucleic Acids Res 18: 5799–5805

    Article  CAS  Google Scholar 

  • Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ (1996) Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 97: 1630–1639

    Article  CAS  Google Scholar 

  • Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, et al (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284–287

    Article  CAS  Google Scholar 

  • Singh S, Verma M, Nain CK, Co L, Goel RC, Sharma BK (1998) Paraoxonase polymorphism in northwestern Indians. Int J Clin Pharmacol Ther 36: 545–548

    CAS  Google Scholar 

  • Singh S, Verma M, Nain CK, Leelamma CO, Goel RC (1999) Paraoxonase (PON1) polymorphism & its relation with lipids in north west Indian Punjabis. Indian J Med Res 110: 133–137

    CAS  Google Scholar 

  • Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, Mizusawa H (1999) No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer’s disease. Neurology 53: 1146–1148

    Article  CAS  Google Scholar 

  • Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN (1999) Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19: 2214–2225

    Article  CAS  Google Scholar 

  • Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, et al (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150: 295–298

    Article  CAS  Google Scholar 

  • Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K (1996) Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57: 69–73

    Article  CAS  Google Scholar 

  • Sun XM, Neuwirth C, Wade DP, Knight BL, Soutar AK (1995) A mutation (T-45C) in the promoter region of the low-density-lipoprotein (LDL)-receptor gene is associated with a mild clinical phenotype in a patient with heterozygous familial hypercholesterolaemia (FH). Hum Mol Genet 4: 2125–2129

    Article  CAS  Google Scholar 

  • Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, Marrugat J (2000) Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients. Arterioscler Thromb Vasc Biol 20: 2113–2119

    Article  CAS  Google Scholar 

  • Tsui LC, Buchwald M, Barker D, Braman JC, Knowlton R, Schumm JW, Eiberg H, et al (1985) Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230: 1054–1057

    Article  CAS  Google Scholar 

  • Van der Gaag MS, Van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, Hendriks HF (1999) Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 147: 405–410

    Article  Google Scholar 

  • Wainwright BJ, Scambler PJ, Schmidtke J, Watson EA, Law HY, Farrall M, Cooke HJ, Eiberg H, Williamson R (1985) Localization of cystic fibrosis locus to human chromosome 7cenq 22. Nature 318: 384–385

    Article  CAS  Google Scholar 

  • Yamasaki Y, Sakamoto K, Watada H, Kajimoto Y, Hori M (1997) The Argl92 isoform of paraoxonase with low sarin-hydrolyzing activity is dominant in the Japanese. Hum Genet 101: 67–68

    Article  CAS  Google Scholar 

  • Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, et al (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17: 3565–3569

    Article  CAS  Google Scholar 

  • Zech R, Zurcher K (1974) Organophosphate splitting serum enzymes in different mammals. Comp Biochem Physiol [B] 48: 427–433

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genome Sciences, Division of Medical Genetics, University of Washington, Seattle, WA, 981995-7360, USA

    Victoria H. Brophy & Clement E. Furlong

  2. Department of Epidemiology, Division of Medical Genetics, University of Washington, Seattle, WA, 981995-7360, USA

    Gail P. Jarvik

  3. Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA, 981995-7360, USA

    Victoria H. Brophy, Gail P. Jarvik & Clement E. Furlong

  4. Roche Molecular Systems, Inc., Pleasanton, CA, USA

    Victoria H. Brophy

Authors
  1. Victoria H. Brophy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gail P. Jarvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clement E. Furlong
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Environmental Health, University of Washington, Seattle, WA, 98195-4695, USA

    Lucio G. Costa

  2. Department of Pharmacology and Physiology, University of Roma “La Sapienza”, Roma, Italy

    Lucio G. Costa

  3. Departments of Genome Sciences and Medicine, Division of Medical Genetics, University of Washington, Seattle, WA, 98195-7720, USA

    Clement E. Furlong

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brophy, V.H., Jarvik, G.P., Furlong, C.E. (2002). PON1 Polymorphisms. In: Costa, L.G., Furlong, C.E. (eds) Paraoxonase (PON1) in Health and Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1027-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1027-7_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5358-4

  • Online ISBN: 978-1-4615-1027-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation